Efficacy of Lisocabtagene maraleucel

The benefits of Lisocabtagene maraleucel were shown in two major studies of more than 300 adult patients with diffuse large B-cell lymphoma (DLBCL) who had not responded to previous treatments or had relapsed after at least two previous courses of treatment or after stem cell transplantation. These studies showed that 53% and 33% of patients treated with lisocabetagen had a complete response (meaning they had no signs of cancer after treatment), and 73% and 61% had at least a partial response.

Another major study involved 184 patients with large B-cell lymphoma (DLBCL, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B) who returned shortly after first-line immunochemotherapy or who did not respond to first-line immunochemotherapy. Patients received either lisocabetagen or standard care, and the study looked at the time before the patients experienced certain outcomes (an "event," meaning their treatment didn't work after nine weeks, they started a different treatment because their treating doctor decided the current drug wasn't working, their cancer worsened, or they died).

The study showed that patients treated with lisocabutagon lived longer without experiencing any events: Those treated with lisocabutagon lived an average of 10.1 months, compared with 2.3 months for those who received standard care. Additionally, after six months, 66% of patients treated with lisocabutagon had a complete response (meaning no signs of cancer after treatment), compared with 39% of patients who received standard treatment.

Since Lisocaptagen has been on the market for a short time, there may be less information on its price and other related information.